Comparative Pharmacology
Head-to-head clinical analysis: ESTRADIOL CYPIONATE versus ESTROVIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTRADIOL CYPIONATE versus ESTROVIS.
ESTRADIOL CYPIONATE vs ESTROVIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol cypionate is a synthetic ester of estradiol, a form of estrogen. It binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene expression and leading to effects such as development of female secondary sexual characteristics, regulation of menstrual cycle, and maintenance of reproductive tissues. It also has effects on bone density, lipid metabolism, and coagulation factors.
Estrovis (estropipate) acts by binding to estrogen receptors (ERα and ERβ), leading to activation of estrogen-responsive genes. It increases hepatic synthesis of sex hormone-binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins, and suppresses gonadotropin secretion via negative feedback on the hypothalamic-pituitary axis.
1-5 mg intramuscularly every 3-4 weeks.
1 mg orally once daily, continuous dosing cycle (no placebo week).
None Documented
None Documented
Terminal elimination half-life is approximately 7–9 days following intramuscular injection, reflecting prolonged absorption from the oil depot.
Terminal elimination half-life: 12-18 hours (mean 15 hours). Clinical context: Supports once-daily dosing; steady-state achieved within 3-5 days.
Primarily renal (approximately 90% as glucuronide and sulfate conjugates; less than 5% as unchanged drug). Biliary/fecal elimination accounts for about 10%.
Renal: 60-70% as glucuronide and sulfate conjugates; Fecal/biliary: 20-30% as conjugated metabolites.
Category D/X
Category C
Estrogen
Estrogen